FINAL REPORT

Cosmetic Efficacy Study

CLINICAL AND NON-INVASIVE INSTRUMENTAL AND DERMATOLOGICAL EVALUATION

Formulation with Paramela oil

Protocol No.: 0040-12B-07E
Study Cosmetic Product: Facial cream
Sponsorship: Hierbas Patagónicas S.R.L

CLAIM
José Bonifacio 717
Buenos Aires
Argentina

Customer
Hierbas Patagónicas S.R.L
Sarmiento 784 – 1º A
Esquel / Chubut Argentina

Person in charge:
Silvia H. Pérez Damonte, MD
Final report date:
June 26, 2012

CLINICAL AND NON-INVASIVE INSTRUMENTAL AND DERMATOLOGICAL EVALUATION

Formulation: Paramela oil

Silvia H. Pérez Damonte
Directora de Claim

Date

Patricia Noemí López
Médica Dermatóloga

Date

Patricia Noemí López, MD
Dermatologist
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0 Objective</td>
<td>4</td>
</tr>
<tr>
<td>2.0 Customer</td>
<td>4</td>
</tr>
<tr>
<td>2.1 Customer Representative</td>
<td>4</td>
</tr>
<tr>
<td>3.0 Study Location</td>
<td>4</td>
</tr>
<tr>
<td>4.0 Study Investigators</td>
<td>4</td>
</tr>
<tr>
<td>5.0 Study Date</td>
<td>4</td>
</tr>
<tr>
<td>6.0 Ethics</td>
<td>5</td>
</tr>
<tr>
<td>6.1 Ethical Conduct of the Study</td>
<td>5</td>
</tr>
<tr>
<td>6.2. Information and Informed Consent</td>
<td>5</td>
</tr>
<tr>
<td>7.0 Study Product</td>
<td>5</td>
</tr>
<tr>
<td>8.0 About Volunteers</td>
<td>5</td>
</tr>
<tr>
<td>9.0 Study Procedures</td>
<td>6</td>
</tr>
<tr>
<td>10.0 Results</td>
<td>8</td>
</tr>
<tr>
<td>11.0 Conclusions</td>
<td>10</td>
</tr>
<tr>
<td>Appendix A- Informed Consent</td>
<td>11</td>
</tr>
<tr>
<td>Appendix B- References</td>
<td>13</td>
</tr>
</tbody>
</table>
1.0 Objectives:
This study aimed at evaluating from the clinical, dermatological and instrumental point of view, through non-invasive methodology, the performance of a formulation with Paramela oil in improving skin conditions with rosacea in healthy female volunteers. This allows to support the following claims:
- Decongestant action
- Anti-inflammatory
- Anti-irritant

2.0 Customer:
Hierbas Patagónicas S.R.L

2.1 Customer Representative:
Q.F. Claudia Groisman

3.0 Study Location
This study has been conducted by CLAIM. José Bonifacio 717. Bs. As. Argentina

4.0 Study Investigators
CEO of CLAIM: Silvia H. Pérez Damonte Pharmacist Specialized in Cosmetic Production. MN 11332
Medical Investigator: Patricia Noemí López, Dermatologist, MN 91915-MP 447405
Statistics Investigator: T.U. Álvaro Favale Mulatieri

5.0 Study Dates
Beginning: June 1, 2012
Final Evaluation: June 22, 2012
6.0 Ethics

6.1 Ethical Conduct of the Study
The study protocol complies with the standards of the The American Society for Testing and Materials (ASTM) and in accordance with the Scientific Committee on Consumer Safety (SCCS) guidance. It meets all international standards for research studies involving human subjects, the Good Clinical Practices (ICH - GCP) and World Medical Association. It has been conducted pursuant to the Declaration of Helsinki (1964), with the amendments of Tokyo (1975), Venice (1983), Hong Kong (1989), Seoul (2008); the standard operative procedures under CLAIM Quality Manual and national standards. Resolution No. 1480-11, Section 6 — The Health Department Resolution No. 1490, dated November 14, which approved the GOOD CLINICAL PRACTICES FOR CLINICAL RESEARCH INVOLVING HUMAN SUBJECTS, is being repealed by the GUIDELINES FOR INVESTIGATIONS INVOLVING HUMAN SUBJECTS.

6.2 Information and Agreement Volunteer Form
All participants were informed about the objective and nature of the study and they all gave their consent in writing before starting the test.

7.0 Study Product:
The study product was provided by Hierbas Patagónicas S.R.L. It was provided in May 2012 and identified as follows: “Formulation with Paramela oil.”

Product Amount: 15 bottles - 50g each
Product Identification: 0040-12
Description: gel cream with characteristic odor.

8.0 About Volunteers
Ten (10) women, with skin sensitive biotype and rosacea, were selected.

Inclusion Criteria:
Age will be determined

- Women having rosacea, sensitive skin, post-inflammatory acne lesions.
• Volunteers will be notified by CLAIM and will receive an explanatory note about the study requirements. They will sign a written informed consent and complete a self-assessment questionnaire.
• Women who are usual users of cosmetic products and are willing and able to meet the study requirements.

Exclusion Criteria:
• Any medical condition or the use of any drug (for example, steroidal and non-steroidal anti-inflammatory drugs), which can increase the participation risk or confuse or affect the study results.
• If you have received an organ transplantation that requires the use of immunosuppressants, (except for corneal transplant).
• If you have diabetes and are insulin-dependent, if you have asthma or respiratory allergy.
• Any dermatological condition, like psoriasis, eczema, atopic dermatitis or folliculitis.
• If you have past medical history of skin reactions to cosmetic application.

9.0 Study Procedures
The study was finished in three (3) weeks. Clinical and instrumental evaluations were performed at baseline and after 21 days of use.

The study staff selected the women eligible for the study and provided them with the study product for the 21 days and the appropriate instructions. Participants used the study product on their face twice a day, in the morning and at night, on clean and dry skin. They avoided exposition to sunlight.

Clinical dermatological evaluation
The ten (10) volunteers were clinically assessed by the dermatologist at baseline and on Day 21.

Bioengineering evaluation
Evaluations were instrumentally performed, in-vivo, with non-invasive methodology, to check the decongestant, anti-inflammatory and anti-irritant action of the study product and its effect on skin erythema.
It was assessed on Day 21.
For the **instrumental evaluation**, the TEWAMETER® 300, of Courage & Khasaka (Germany) was used. For the skin erythema, the equipment used was Chromameter® 400 Minolta.

**VOLUNTEER PARTICIPANTS**

<table>
<thead>
<tr>
<th></th>
<th>INITIALS</th>
<th>AGE</th>
<th>SEX</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NM</td>
<td>43</td>
<td>F</td>
</tr>
<tr>
<td>2</td>
<td>EP</td>
<td>37</td>
<td>F</td>
</tr>
<tr>
<td>3</td>
<td>GP</td>
<td>43</td>
<td>F</td>
</tr>
<tr>
<td>4</td>
<td>PB</td>
<td>44</td>
<td>F</td>
</tr>
<tr>
<td>5</td>
<td>MAF</td>
<td>48</td>
<td>F</td>
</tr>
<tr>
<td>6</td>
<td>CB</td>
<td>47</td>
<td>F</td>
</tr>
<tr>
<td>7</td>
<td>LM</td>
<td>25</td>
<td>F</td>
</tr>
<tr>
<td>8</td>
<td>JA</td>
<td>37</td>
<td>F</td>
</tr>
<tr>
<td>9</td>
<td>FS</td>
<td>42</td>
<td>F</td>
</tr>
<tr>
<td>10</td>
<td>SMM</td>
<td>49</td>
<td>F</td>
</tr>
</tbody>
</table>
RESULTS:

STUDY OF TRANSEPIDERMAL WATER LOSS (TEWL)

Anti-irritant and anti-inflammatory power check

Formulation: Paramela oil

This study has been performed at constant temperature (25 °C) and humidity (52%)

Reference table

<table>
<thead>
<tr>
<th>TEWL-values g/h/m²</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-10</td>
<td>very healthy condition</td>
</tr>
<tr>
<td>10-15</td>
<td>healthy condition</td>
</tr>
<tr>
<td>15-25</td>
<td>NORMAL condition</td>
</tr>
<tr>
<td>25-30</td>
<td>strained skin</td>
</tr>
<tr>
<td>above 30</td>
<td>critical condition</td>
</tr>
</tbody>
</table>
10.0 Statistical Results:

**Instrumental measures of skin erythema**

Instrumental measures of the skin erythema of the participants were taken using the Chromameter Minolta colorimeter at baseline and on Day 21. The colorimeter determines the skin color by using the color space L*a*b* (also called CIELAB). In this case, the parameter a* was determined, which is a measure of the red degree (positive values indicate red), equivalent to skin erythema.

To assess the treatment influence on this parameter, a variance analysis was carried out on the obtained data, being evaluation instance and the study participants the variation factors.

As noted on Table 1, for a 99.9% confidence level, it can be concluded that after 21 days of treatment, the study product significantly reduced the average value of parameter a*, meaning that it significantly reduced skin redness. In such instance, the average reduction of parameter a* reached 28.8% compared to baseline (Table 2).

**Table 1** Average values of the instrumental color parameter a* of study subject’s skin in the two evaluation instances considered.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Evaluation instance</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Day 21</td>
<td></td>
</tr>
<tr>
<td>a* ***</td>
<td>23.1 b</td>
<td>16.4 a</td>
<td></td>
</tr>
</tbody>
</table>

The parameters marked with *** correspond to those in which treatment resulted in significant changes for a 99.9% confidence level.

The average values for a parameter with different letters correspond to values, which are significantly different according to Tukey’s Test, with a confidence level of 95%.

After 21 days of treatment, all study subjects experienced a reduction in parameter a* (Table 2), indicating that the study product efficiently reduced the skin erythema of all the study subjects.

**Table 2** Average improvement in the value of the instrumental color parameter a* of study subject’s skin compared to the evaluation performed before the beginning of treatment; and percentage of study subjects who improved after 21 days of treatment.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Average improvement compared to value at baseline</th>
<th>Percentage of study subjects who improved</th>
</tr>
</thead>
<tbody>
<tr>
<td>a*</td>
<td>28.8%</td>
<td>100%</td>
</tr>
</tbody>
</table>

For improvement, we mean a reduction in parameter a*. 
11.0 Conclusions

Through clinical, dermatological and instrumental “in-vivo” evaluation, the behavior of a formulation with Paramela oil was assessed in improving sensitive skins and rosacea. It has been shown that not only the skin barrier was not affected, since the TEWL values obtained were lower than the values at baseline, but also the erythema diminished by 28.8% compared to the beginning of treatment.

Therefore, it has been proved the good performance of the formulation with Paramela oil in improving the condition of sensitive skins and rosacea due to its anti-irritant, anti-inflammatory and decongestant action.

Silvia H. Pérez Damonte
CEO CLAIM
Appendix A:

Consent No.: 0040-12B

SUBJECT'S CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY

I have been told about the possibility to take part in a clinical research study to assess the efficacy of a cosmetic product with decongestant, anti-inflammatory and anti-irritant action. This product has been studied only in its tolerance through other testing methods. The study Sponsor would like to prove its efficacy.

I have been told that I will be using the cosmetic product twice a day (during the morning and at night). During the study, I should not use any other product on those areas and should not have any beauty treatment performed until the study ends and I go to CLAIM.

I have been told that I cannot take part in this study if I am pregnant or have the possibility to become pregnant.

I have been told that the study lasts 21 days and that I should attend two study visits: on Day 0 and on Day 21. In each study visit, the areas studied will be measured using non-invasive equipment. The alteration in skin barriers will be measured with a Tewameter and the skin erythema will be measured using a colorimeter Chromameter Minolta.

I have been told that if the skin area treated with the study product becomes red or irritated or if I experience any reaction due to the study product, I should immediately report that since it may lead to the research discontinuation. If applying the study product causes irritation or any other side effect, I will receive the corresponding medical treatment free of charge. By “medical treatment”, we mean visit to a physician or hospital service and the drugs medically necessary to treat or relieve the effects produced by the study product or the study procedure.

I have been told that the results will be reported to study customer who should analyze and inform them in due manner and form to the INAME or corresponding sanitary entity. My personal data will be kept confidential and only the study site, its staff and the study customer will have access to it. The data and the photographs taken will only be used for this study purposes. CLAIM is registered in Dirección Nacional de Protección de Datos (National Department of Personal Data Protection), Act No. 25326.

I have been told that participation in this study is voluntary and that I can withdraw from it for the following reasons: Unexpected personal reasons or circumstances that impede the future participation or because clinical data suggests that I should not continue participating.

I have been told that participation in this study is voluntary and that I can withdraw from it for the following reasons: Unexpected personal reasons or circumstances that impede the future participation or because clinical data suggests that I should not continue participating.
MANDATORY RESPONSIBILITY OF STUDY PARTICIPANTS
and who to contact:

IN THE EVENT ANY SIDE EFFECT MAY APPEAR, THE STUDY SUBJECT SHALL IMMEDIATELY CONTACT CLAIM AND GO PERSONALLY IF REQUESTED.

If you have any concern about the study, contact Silvia H. Pérez Damonte To report any adverse effect, contact Patricia Noemi López, MD

CLAIM
José Bonifacio 715
Bs AS, CP 1424
Argentina
4431 – 9564 o 4433- 2732

Participants will receive the amount of $__________ after study ends.

I will receive a copy of the agreement form.

I HAVE READ, UNDERSTOOD AND ACCEPTED everything that is written in this informed consent.

Participant Signature and Name--------------------------------------------

ID No. ---------------------------------------------------------------

Date----------------------------------------------------------------------------

Technical Director -------------M Nº 11332 Silvia H. Perez Damonte-------------------

Thanks for participating
CLAIM
Appendix B: BIBLIOGRAPHY REFERENCE


- EEMCO Guidance on Assessment of Cosmetic Efficacy by Human Volunteer Testing General Consideration.